Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-12-12

Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating Basmisanil in children with Dup15q Syndrome was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Basmisanil (basmisanil)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Dup15q Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2025-12-12